PHAT Stock Overview
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Phathom Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.58 |
| 52 Week High | US$19.71 |
| 52 Week Low | US$5.07 |
| Beta | 0.64 |
| 1 Month Change | -6.84% |
| 3 Month Change | -37.65% |
| 1 Year Change | -43.81% |
| 3 Year Change | -65.45% |
| 5 Year Change | -85.69% |
| Change since IPO | -77.32% |
Recent News & Updates
Recent updates
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
Dec 11Following Up On Phathom Pharmaceuticals
Sep 03Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Jun 26Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
Mar 18Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30
Aug 02The Prognosis For Phathom Pharmaceuticals
Jun 22Phathom Pharmaceuticals: Undiscovered Gem
Jan 20Phathom Pharma prices equity offering at $42
Dec 17Phathom Pharma launches equity offering
Dec 15Phantom Pharma completes enrollment in late-stage study of lead candidate in esophagus inflammation disorder
Nov 30Shareholder Returns
| PHAT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -3.1% |
| 1Y | -43.8% | 3.8% | 13.1% |
Return vs Industry: PHAT underperformed the US Pharmaceuticals industry which returned 4.2% over the past year.
Return vs Market: PHAT underperformed the US Market which returned 13.1% over the past year.
Price Volatility
| PHAT volatility | |
|---|---|
| PHAT Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PHAT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PHAT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 452 | Terrie Curran | www.phathompharma.com |
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Phathom Pharmaceuticals, Inc. Fundamentals Summary
| PHAT fundamental statistics | |
|---|---|
| Market cap | US$356.25m |
| Earnings (TTM) | -US$339.44m |
| Revenue (TTM) | US$26.27m |
14.5x
P/S Ratio-1.1x
P/E RatioIs PHAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHAT income statement (TTM) | |
|---|---|
| Revenue | US$26.27m |
| Cost of Revenue | US$4.33m |
| Gross Profit | US$21.95m |
| Other Expenses | US$361.39m |
| Earnings | -US$339.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 06, 2025
| Earnings per share (EPS) | -4.96 |
| Gross Margin | 83.54% |
| Net Profit Margin | -1,292.14% |
| Debt/Equity Ratio | -277.0% |
How did PHAT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/04 19:56 |
| End of Day Share Price | 2025/03/04 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Phathom Pharmaceuticals, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Umer Raffat | Evercore ISI |